BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 10598942)

  • 1. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
    Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
    J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.
    Koeppe RA; Frey KA; Kume A; Albin R; Kilbourn MR; Kuhl DE
    J Cereb Blood Flow Metab; 1997 Sep; 17(9):919-31. PubMed ID: 9307605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
    Koeppe RA; Frey KA; Vander Borght TM; Karlamangla A; Jewett DM; Lee LC; Kilbourn MR; Kuhl DE
    J Cereb Blood Flow Metab; 1996 Nov; 16(6):1288-99. PubMed ID: 8898703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.
    Chan GL; Holden JE; Stoessl AJ; Samii A; Doudet DJ; Dobko T; Morrison KS; Adam M; Schulzer M; Calne DB; Ruth TJ
    J Nucl Med; 1999 Feb; 40(2):283-9. PubMed ID: 10025836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of the brain vesicular monoamine transporter.
    Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
    J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
    Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
    Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.
    Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K
    Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.
    Huang ZR; Tsai CL; Huang YY; Shiue CY; Tzen KY; Yen RF; Hsin LW
    PLoS One; 2016; 11(9):e0161295. PubMed ID: 27612194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
    Meyer P; Bohnen NI; Minoshima S; Koeppe RA; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
    Neurology; 1999 Jul; 53(2):371-4. PubMed ID: 10430428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo measurement of the vesicular monoamine transporter in schizophrenia.
    Taylor SF; Koeppe RA; Tandon R; Zubieta JK; Frey KA
    Neuropsychopharmacology; 2000 Dec; 23(6):667-75. PubMed ID: 11063922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
    De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
    Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter.
    DaSilva JN; Kilbourn MR; Mangner TJ
    Appl Radiat Isot; 1993 Dec; 44(12):1487-9. PubMed ID: 7903060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain.
    Kilbourn MR
    Nucl Med Biol; 2004 Jul; 31(5):591-5. PubMed ID: 15219277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat pancreas uptake of [11C]dihydrotetrabenazine stereoisomers.
    Kilbourn MR
    Nucl Med Biol; 2010 Nov; 37(8):869-71. PubMed ID: 21055616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
    Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
    Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.